**Discussion**

Additional analyses of OS and other selected OS hazard ratios are provided in the Supporting Information.

**Acknowledgements**

The authors thank all patients and their families, study participants, and site investigators. The authors also thank the members of the steering committee, the data monitoring committee, and the TOPAZ-1 study team. The authors also acknowledge the support of the National Cancer Institute (U10CA094444) and the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK092390). The authors also thank the members of the steering committee, the data monitoring committee, and the TOPAZ-1 study team. The authors also acknowledge the support of the National Cancer Institute (U10CA094444) and the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK092390).

**References**


